Citations

Clear

6055 citation(s) found for "Vu, Peter".

Characterization of GANAB Phenotype in Patients with ADPKD Using Advanced Imaging Biomarkers
Debeh, Fadi George Munairdjy , Rangarajan, Vineetha, Borghol, Abdul Hamid , Paul, Stefan N., Alkhatib, Bassel , Nader, Nay, Gregory, Adriana , Yang, Hana , Dahl, Neera K. , Kline, Timothy L. , Dahl, Neera K , Rangarajan, Vineetha, Ghanem, Ahmad , Nader, Nay, Hanna, Christian , Harris, Peter C. , Chebib, Fouad T.

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024xrre28mc Get It

Role of Advanced Imaging Metrics in Predicting Outcomes in Patients Affected with Polycystic Kidney Disease
Kline, Timothy L. , Gregory, Adriana , Cohen, Aarón , Ables, Erin , Landsittel, Douglas , Chapman, Arlene B., Mrug, Michal , Ables, Erin , Chebib, Fouad T. , Torres, Vicente E. , Harris, Peter C. , Rahbari-Oskoui, Frederic F. , Yu, Alan S.L.

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024fjzsk0f5 Get It

Renal Uric Acid Crystals Trigger Cystogenesis and CKD in Polycystic Kidney Disease
Holznecht, Nickolas J., Strubl, Sebastian , Mueller, Roman-Ulrich, Torres, Jacob A. , Harris, Peter C. , Weimbs, Thomas

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024xw9pwnwn Get It

Characterization of IFT140 Phenotype in Patients with ADPKD Using Advanced Imaging Biomarkers
Debeh, Fadi George Munairdjy , Borghol, Abdul Hamid , Paul, Stefan N., Alkhatib, Bassel , Nader, Nay, Gregory, Adriana , Yang, Hana , Dahl, Neera K. , Kline, Timothy L. , Dahl, Neera K , Ghanem, Ahmad , Nader, Nay, Hanna, Christian , Harris, Peter C. , Chebib, Fouad T.

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.20240vzj2pha Get It

ADPKD-Spectrum Phenotype in Carriers of IFT172 Pathogenic Variants
Elbarougy, Doaa E. , Jameel, Rohail, Yang, Hana , Schauer, R., Rogers, Sean A, Frank, Jacob A., Jun, Ma , Zagorec, Nikola , Audrézet, Marie‐Pierre , Elbarougy, Doaa E , Schauer, Rachel S., McDonnell, Shannon K. , Ma, Jun, Sayer, John A , Gall, Émilie Cornec-Le , Larson, Nicholas B. , Harris, Peter C.

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024jcj3kpb3 Get It

Individuals Heterozygous for SLC34A3 Predicted Pathogenic Variants Are at Increased Risk of Nephrolithiasis
Chang, Alex R. , Cogal, Andrea G. , Frank, Jacob A., Scheinman, Steven J., Ma, Jun , Chang, Alexander R , Moore, Bryn S. , Luo, Jonathan Z. , Bucaloiu, Ion Dan , McDonnell, Shannon K. , Harris, Peter C. , Lieske, John C.

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.20242524yrwv Get It

Joint Modeling of Longitudinal Ferritin Trajectories and COVID-19 Infections in Native American, Hispanic, and White Patients on Hemodialysis
Hu, Mingzhao, Wang, Yuedong , Conway, Baqiyyah , Quandelacy, Talía M. , Kotanko, Peter

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024sb37e8r9 Get It

Artificial intelligence-enabled electrocardiogram for left ventricular diastolic dysfunction and long-term risk of new-onset atrial fibrillation
Tsaban, Gal , Lee, Emma , Wopperer, Samuel B., Abbasi, Mehdi , Yu, Hee Tae , Kane, Garvan C. , Deshmukh, Abhishek , Friedman, Paul A. , Oh, Jae K. , López-Jiménez, Francisco , Asirvatham, Samuel J. , Noseworthy, Peter A. , Attia, Zachi I. , Oh, Jae K.

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.469 Get It

Abstract Background Heart failure (HF) and atrial fibrillation (AF) are intertwined, sharing common risk factors and influencing each other in a reciprocal manner. While left ventricular diastolic dysfunction (LVDD) stands as a hallmark of HF's hemodynamic profile, its direct correlation with heightened AF risk remains uncertain. Our recent validation of an artificial intelligence-enabled electrocardiogram (AI-ECG) algorithm for LVDD detection has opened new avenues. Yet, whether AI-ECG-detected LVDD correlates with long-term AF risk remains unexplored. Methods We performed a retrospective study among all patients with a comprehensive LVDD assessment from the test population of the AI-ECG LVDD study between September 2001 and June 2022. Patients with prior documented AF according to health records or previous ECG were excluded. Patients were classified by AI-ECG as normal diastolic function (DF), grade 1 (G1), grade 2 (G2), or grade 3 (G3) LVDD. We assessed the risk of AF across AI-ECG LVDD grade, with normal DF as reference, with competing risk models. Results Of 97,023 patients free of AF at baseline, 63,533 (65.4%), 10,776 (11.1%), 18,940 (19.5%), and 3,774 (3.9%) were classified as normal DF, G1-LVDD, G2-LVDD, and G3-LVDD, respectively. Worse AI-ECG LVDD was associated with older age, lower left ventricular ejection fraction (LVEF), and higher rates of HF, diabetes, hypertension, chronic pulmonary disease, renal failure, and cardiovascular disease (p-of-trend<0.001 for all). Over a median follow-up of 4.8 years (interquartile range 1.8-9.2 years), new-onset AF occurred in 6,795 (7.0%) patients. In multivariable survival analysis, adjusted to multiple risk factors including LVEF and clinical HF, G2 and G3 LVDD, representing patients with high filling pressures, were independently associated with a higher AF-risk [G2-LVDD: adjusted hazard ratio (aHR) 1.64 (95% confidence interval (95%CI) 1.52-1.73), G3-LVDD: aHR 2.24 (95%CI 2.02-2.48)]. Conclusion The AI-ECG LVDD algorithm independently predicts long-term AF risk, regardless of LVEF and clinical HF status, highlighting its potential for identifying high-risk populations and guiding proactive monitoring and management.
Quality of life measures with etripamil self-administration for acute episodes of paroxysmal supraventricular tachycardia in a medically unsupervised setting: patient-reported outcomes from NODE-303
Camm, A. John, Coutu, Benoit , Parody, Maria Lenor, Singh, Narendra Kumar , Stambler, Bruce S. , Tahirkheli, Naeem Khan, Agudelo-Uribe, Juan F., Szakács, Comdr.JenöE., Shardonofsky, Silvia, Bharucha, David B. , Ip, James E. , Noseworthy, Peter A. , Rafii, F, Sears, Samuel F.

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.631 Get It

Abstract Background Etripamil nasal spray (NS) is a fast-acting, self-administered calcium-channel blocker in development for the conversion of AV-nodal dependent paroxysmal supraventricular tachycardia (PSVT) in a medically unsupervised setting. Prior studies show favorable safety and efficacy in converting single episodes of PSVT to sinus rhythm (SR). Purpose In NODE-303, patient-reported outcome (PRO) instruments assessed quality of life (QoL) over multiple etripamil-treated episodes of PSVT. Methods NODE-303 was an event-driven, multi-center, open-label Phase 3 study in North and South American patients with documented PSVT that evaluated the safety and efficacy of etripamil in PSVT termination, over multiple episodes and without the need for prior test dosing. Enrolled patients who perceived PSVT symptoms applied an ambulatory ECG cardiac monitoring system (CMS), performed a pre-trained vagal maneuver and, if symptoms persisted, self-administered etripamil NS 70 mg. A study amendment allowed a repeat dose (etripamil NS, 70 mg) if symptoms persisted 10 min after the first dose. Each patient could self-treat up to 4 episodes. Safety was assessed through adverse events, clinical data, and ECG CMS recordings. The Treatment Satisfaction Questionnaire for Medication (TSQM; validated for acute episodic assessments) and other PROs were administered, and healthcare utilization data were acquired. Patients completed PROs at baseline (BL), monthly, and per PSVT episode, which collected information on symptoms, episode characteristics, rescue medications, and emergency room visits. Additional PROs were the Brief Illness Perception Questionnaire (BIPQ), Cardiac Anxiety Questionnaire (CAQ), and 36-Item Short Form Health Survey (SF-36). Results There were higher proportions of patients reporting mild, minimal or no disease severity, every 6 months, than at BL; extremely severe, severe, and moderate disease severity was reported by smaller proportions of patients than at BL, though incomplete surveys at later visits may limit this analysis. Anxiety and stress about future PSVT episodes were consistently reduced from BL. Measures of treatment satisfaction, effectiveness, and convenience were consistent across multiple episodes, and were at levels considered favorable for the TSQM instrument (Table 1). Rates of emergency-room visits and hospital admissions across multiple, treated PSVT episodes were similar to those observed in trials assessing single episodes (Table 2). The BIPQ, CAQ or SF-36 had no notable changes from BL. Conclusions Etripamil self-administration was associated with patient-reported improvements in degree of disease severity, decreased anxiety and stress over future PSVT episodes, and levels of treatment satisfaction, effectiveness, and convenience considered favorable for respective PRO instrument. Using a symptom-prompted, self-administered treatment for PSVT could potentially improve QoL measures and reduce healthcare resource utilization.
The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society Clinical Practice Guidelines for the Management of Varicose Veins of the Lower Extremities. Part II: Endorsed by the Society of Interventional Radiology a
Lawrence, Peter F. , Wasan, Suman , Meissner, Mark H. , Almeida, José I. , Brown, Kellie R. , Bush, Ruth L., Iorio, Michael Di, Fish, John, Gloviczki, Monika L. , Jayaraj, Arjun , Obi, Andrea T., Ozsvath, Kathleen J., Singh, Michael J. , Vayuvegula, Satish, Welch, Harold J. , Gloviczki, Péter , Fukaya, Eri , Hingorani, Anil , Kolluri, Raghu , Murad, M. Hassan , Obi, Andrea T.

Mayo Clinic

Annals of Phlebology | October 28, 2024 | Volume: 22 | Issue: Suppl 1 | Pages: S1-S77

10.37923/phle.2024.22.s.s1 Get It